Search Results - "Adamia, Sophia"

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications by Ogiya, Daisuke, Liu, Jiye, Ohguchi, Hiroto, Kurata, Keiji, Samur, Mehmet K., Tai, Yu-Tzu, Adamia, Sophia, Ando, Kiyoshi, Hideshima, Teru, Anderson, Kenneth C.

“…Anti-CD38 monoclonal antibody (MoAb) treatments including daratumumab (DARA) are effective therapies for both newly diagnosed and relapsed multiple myeloma…”
Get full text

Inhibition of USP10 induces degradation of oncogenic FLT3 by Weisberg, Ellen L, Schauer, Nathan J, Yang, Jing, Lamberto, Ilaria, Doherty, Laura, Bhatt, Shruti, Nonami, Atsushi, Meng, Chengcheng, Letai, Anthony, Wright, Renee, Tiv, Hong, Gokhale, Prafulla C, Ritorto, Maria Stella, De Cesare, Virginia, Trost, Matthias, Christodoulou, Alexandra, Christie, Amanda, Weinstock, David M, Adamia, Sophia, Stone, Richard, Chauhan, Dharminder, Anderson, Kenneth C, Seo, Hyuk-Soo, Dhe-Paganon, Sirano, Sattler, Martin, Gray, Nathanael S, Griffin, James D, Buhrlage, Sara J

“…An inhibitor of the deubiquitinase (DUB) USP10 regulates the degradation of oncogenic FLT3, thus defining USP10 as a DUB for FLT3 and providing a therapeutic…”
Get full text

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells by Cea, Michele, Cagnetta, Antonia, Adamia, Sophia, Acharya, Chirag, Tai, Yu-Tzu, Fulciniti, Mariateresa, Ohguchi, Hiroto, Munshi, Aditya, Acharya, Prakrati, Bhasin, Manoj K., Zhong, Lei, Carrasco, Ruben, Monacelli, Fiammetta, Ballestrero, Alberto, Richardson, Paul, Gobbi, Marco, Lemoli, Roberto M., Munshi, Nikhil, Hideshima, Teru, Nencioni, Alessio, Chauhan, Dharminder, Anderson, Kenneth C.

“…Multiple myeloma (MM) is characterized by a highly unstable genome, with aneuploidy observed in nearly all patients. The mechanism causing this karyotypic…”
Get full text

Inhibition of the deubiquitinase USP10 induces degradation of SYK by Yang, Jing, Meng, Chengcheng, Weisberg, Ellen, Case, Abigail, Lamberto, Ilaria, Magin, Robert S., Adamia, Sophia, Wang, Jinhua, Gray, Nathanael, Liu, Suiyang, Stone, Richard, Sattler, Martin, Buhrlage, Sara, Griffin, James D.

“…Background There is growing evidence that spleen tyrosine kinase (SYK) is critical for acute myeloid leukaemia (AML) transformation and maintenance of the…”
Get full text

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma by Adamia, Sophia, Bhatt, Shruti, Wen, Kenneth, Chyra, Zuzana, Fell, Geoffrey G., Tai, Yu-Tzu, Pioso, Marisa S., Abiatari, Ivane, Letai, Anthony, Dorfman, David M., Hideshima, Teru, Anderson, Kenneth C.

“…Oncogenic activated RAS mutations have been detected in 50% of de novo and 70% of relapsed multiple myeloma (MM) patients. Translocation t(11;14) involving…”
Get full text

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia by Weisberg, Ellen, Meng, Chengcheng, Case, Abigail, Sattler, Martin, Tiv, Hong L., Gokhale, Prafulla C., Buhrlage, Sara, Wang, Jinhua, Gray, Nathanael, Stone, Richard, Liu, Suiyang, Bhagwat, Shripad V., Tiu, Ramon V., Adamia, Sophia, Griffin, James D.

Get full text

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma by Adamia, Sophia, Abiatari, Ivane, Amin, Samir B., Fulciniti, Mariateresa, Minvielle, Stephane, Li, Cheng, Moreau, Philippe, Avet-Loiseau, Herve, Munshi, Nikhil C., Anderson, Kenneth C.

“…Over the last few years, a detailed map of genetic and epigenetic lesions that underlie multiple myeloma (MM) has been created. Regulation of microRNA…”
Get full text

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications by Jakubikova, Jana, Adamia, Sophia, Kost-Alimova, Maria, Klippel, Steffen, Cervi, David, Daley, John F., Cholujova, Dana, Kong, Sun-Young, Leiba, Merav, Blotta, Simona, Ooi, Melissa, Delmore, Jake, Laubach, Jacob, Richardson, Paul G., Sedlak, Jan, Anderson, Kenneth C., Mitsiades, Constantine S.

“…Recurrence of multiple myeloma (MM) after therapy suggests the presence of tumor-initiating subpopulations. In our study, we performed flow cytometry–based…”
Get full text

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia by Weisberg, Ellen, Meng, Chengcheng, Case, Abigail, Sattler, Martin, Tiv, Hong L., Gokhale, Prafulla C., Buhrlage, Sara, Wang, Jinhua, Gray, Nathanael, Stone, Richard, Liu, Suiyang, Bhagwat, Shripad V., Tiu, Ramon V., Adamia, Sophia, Griffin, James D.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs by LELEU, Xavier, SOUMERAI, Jacob, MOREAU, Anne-Sophie, PATTERSON, Christopher J, GHOBRIAL, Irene M, TREON, Steven P, ROCCARO, Aldo, HATJIHARISSI, Evdoxia, HUNTER, Zachary R, MANNING, Robert, CICCARELLI, Bryan T, SACCO, Antonio, IOAKIMIDIS, Leukothea, ADAMIA, Sophia

“…Nucleoside analogs (NAs) are considered as appropriate agents in the treatment of Waldenström macroglobulinemia (WM), a lymphoplasmacytic lymphoma. Sporadic…”
Get full text

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells by Weisberg, Ellen, Ray, Arghya, Nelson, Erik, Adamia, Sophia, Barrett, Rosemary, Sattler, Martin, Zhang, Chengsheng, Daley, John F, Frank, David, Fox, Edward, Griffin, James D

“…Clinical responses achieved with FLT3 kinase inhibitors in acute myeloid leukemia (AML) are typically transient and partial. Thus, there is a need for…”
Get full text

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics by Ogiya, Daisuke, Chyra, Zuzana, Verselis, Sigitas J., O’Keefe, Morgan, Cobb, Jacquelyn, Abiatari, Ivane, Talluri, Srikanth, Sithara, Anjana Anilkumar, Hideshima, Teru, Chu, Michael P., Hájek, Roman, Dorfman, David M., Pilarski, Linda M., Anderson, Kenneth C., Adamia, Sophia

“…Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell…”
Get full text

Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets by Adamia, Sophia, Pilarski, Patrick M, Belch, Andrew R, Pilarski, Linda M

“…Current evidence suggests a significant role of aberrant splicing in the development and maintenance of malignancy. This multistep, tightly regulated…”
Get more information

Aberrant Posttranscriptional Processing of Hyaluronan Synthase 1 in Malignant Transformation and Tumor Progression by Adamia, Sophia, Kriangkum, Jitra, Belch, Andrew R., Pilarski, Linda M.

“…It is becoming increasingly apparent that splicing defects play a key role in cancer, and that alterations in genomic splicing elements promote aberrant…”
Get full text

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells by Weisberg, Ellen, Wright, Renee D, McMillin, Douglas W, Mitsiades, Constantine, Ray, Arghya, Barrett, Rosemary, Adamia, Sophia, Stone, Richard, Galinsky, Ilene, Kung, Andrew L, Griffin, James D

“…Clinical studies of patients with chronic myeloid leukemia revealed that a common pattern of response is a dramatic fall in the circulating population of blast…”
Get full text

Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer by Kuppusamy, Hemalatha, Ogmundsdottir, Helga M, Baigorri, Eva, Warkentin, Amanda, Steingrimsdottir, Hlif, Haraldsdottir, Vilhelmina, Mant, Michael J, Mackey, John, Johnston, James B, Adamia, Sophia, Belch, Andrew R, Pilarski, Linda M

“…Genetic variations in the hyaluronan synthase 1 gene (HAS1) influence HAS1 aberrant splicing. HAS1 is aberrantly spliced in malignant cells from multiple…”
Get full text

A combined dielectrophoresis, traveling wave dielectrophoresis and electrorotation microchip for the manipulation and characterization of human malignant cells by Cen, Esther G., Dalton, Colin, Li, Youlan, Adamia, Sophia, Pilarski, Linda M., Kaler, Karan V.I.S.

“…The study of the dielectric properties of micrometer- or nanometer-scale particles is of particular interest in present-day applications of biomedical…”
Get full text

Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? by Adamia, Sophia, Pilarski, Patrick M, Bar-Natan, Michal, Stone, Richard M, Griffin, James D

“…Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to…”
Get more information

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma by Maxwell, Christopher A., Rasmussen, Erik, Zhan, Fenghuang, Keats, Jonathan J., Adamia, Sophia, Strachan, Erin, Crainie, Mary, Walker, Ronald, Belch, Andrew R., Pilarski, Linda M., Barlogie, Bart, Shaughnessy, John, Reiman, Tony

“…Multiple myeloma (MM) plasma cells (PCs) express receptor for hyaluronan-mediated motility (RHAMM), a hyaluronan-binding, cytoskeleton and centrosome protein…”
Get full text

Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma by Adamia, Sophia, Reiman, Tony, Crainie, Mary, Mant, Michael J., Belch, Andrew R., Pilarski, Linda M.

“…In this study, we show that the hyaluronan synthase 1 (HAS1) gene undergoes aberrant intronic splicing in multiple myeloma (MM). In addition to HAS1 full…”
Get full text